Testing nafamostat to reduce bleeding risk during dialysis
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are on hemodialysis and considered high risk for bleeding
- You have very low platelets (less than 10,000), or abnormal blood clotting tests (PTT over 60 seconds and/or INR above 2)
- You are having active bleeding or have had bleeding problems (such as nose/eye bleeding or blood in urine)
- You had a brain bleed within the last 6 months, or you are taking blood-thinning medicines (warfarin/Coumadin or NOACs), and/or two antiplatelet medicines
- You recently had major surgery within the last month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medications, tranexamic acid and desmopressin, to see if they can reduce bleeding during surgery in people with severe kidney disease or on dialysis. The results may help make surgery safer for you.
This trial tests a new medicine called nafamostat to prevent blood clots during continuous dialysis (CRRT), for people who are at high risk of bleeding or can't take heparin.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This trial tests an experimental drug called nafamostat mesilate to help control blood clotting problems in people with severe infections (sepsis). It aims to reduce the risk of abnormal blood clots that can harm organs.
This trial tests a medicine called nafamostat mesilate to prevent blood clots in patients who need ECMO (a machine that helps your heart and lungs) after heart surgery. It may offer a safer way to thin the blood compared to standard treatments.
This trial is testing a medicine called nafamostat mesylate for people with sepsis (a severe infection) that causes blood clotting problems and who are receiving hemofiltration (a type of blood filtering). The goal is to see if this medicine helps improve their recovery.
Hear when a new Dialysis; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.